The role of delamanid in the treatment of drug-resistant tuberculosis

Joe Lewis; Derek J. Sloan

doi:10.2147/tcrm.s71076

The role of delamanid in the treatment of drug-resistant tuberculosis

Joe Lewis
, Derek J. Sloan

Clinical Sciences

Liverpool University Hospitals NHS Foundation Trust
Liverpool School of Tropical Medicine
Liverpool Heart and Chest Hospital NHS Foundation Trust

Research output: Contribution to journal › Review article › peer-review

83 Citations (Scopus)

Abstract

Tuberculosis (TB) remains a significant cause of death worldwide, and emergence of drug-resistant TB requires lengthy treatments with toxic drugs that are less effective than their first-line equivalents. New treatments are urgently needed. Delamanid, previously OPC-67863, is a novel drug of the dihydro-nitroimidazole class with potent anti-TB activity and great promise to be effective in the treatment of drug-resistant TB. This review examines the preclinical and clinical development of delamanid, reviews current guidance on its use and evaluates the opportunities and challenges for its future role in TB management.

Original language	English
Pages (from-to)	779-791
Number of pages	13
Journal	Therapeutics and Clinical Risk Management
Volume	11
DOIs	https://doi.org/10.2147/tcrm.s71076
Publication status	Published - 13 May 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Delamanid
Drug resistance
MDR-TB
OPC-67683
Tuberculosis

Access to Document

10.2147/tcrm.s71076Licence: CC BY-NC

TCRM-71076-update-on-the-management-of-multidrug--resistant-tuberculosi 051315Final published version, 454 KBLicence: CC BY-NC

Cite this

@article{3225a41091af41a487de825913cbe5d5,

title = "The role of delamanid in the treatment of drug-resistant tuberculosis",

abstract = "Tuberculosis (TB) remains a significant cause of death worldwide, and emergence of drug-resistant TB requires lengthy treatments with toxic drugs that are less effective than their first-line equivalents. New treatments are urgently needed. Delamanid, previously OPC-67863, is a novel drug of the dihydro-nitroimidazole class with potent anti-TB activity and great promise to be effective in the treatment of drug-resistant TB. This review examines the preclinical and clinical development of delamanid, reviews current guidance on its use and evaluates the opportunities and challenges for its future role in TB management.",

keywords = "Delamanid, Drug resistance, MDR-TB, OPC-67683, Tuberculosis",

author = "Joe Lewis and Sloan, \{Derek J.\}",

year = "2015",

month = may,

day = "13",

doi = "10.2147/tcrm.s71076",

language = "English",

volume = "11",

pages = "779--791",

journal = "Therapeutics and Clinical Risk Management",

issn = "1176-6336",

publisher = "Dove Medical Press Ltd",

}

TY - JOUR

T1 - The role of delamanid in the treatment of drug-resistant tuberculosis

AU - Lewis, Joe

AU - Sloan, Derek J.

PY - 2015/5/13

Y1 - 2015/5/13

N2 - Tuberculosis (TB) remains a significant cause of death worldwide, and emergence of drug-resistant TB requires lengthy treatments with toxic drugs that are less effective than their first-line equivalents. New treatments are urgently needed. Delamanid, previously OPC-67863, is a novel drug of the dihydro-nitroimidazole class with potent anti-TB activity and great promise to be effective in the treatment of drug-resistant TB. This review examines the preclinical and clinical development of delamanid, reviews current guidance on its use and evaluates the opportunities and challenges for its future role in TB management.

AB - Tuberculosis (TB) remains a significant cause of death worldwide, and emergence of drug-resistant TB requires lengthy treatments with toxic drugs that are less effective than their first-line equivalents. New treatments are urgently needed. Delamanid, previously OPC-67863, is a novel drug of the dihydro-nitroimidazole class with potent anti-TB activity and great promise to be effective in the treatment of drug-resistant TB. This review examines the preclinical and clinical development of delamanid, reviews current guidance on its use and evaluates the opportunities and challenges for its future role in TB management.

KW - Delamanid

KW - Drug resistance

KW - MDR-TB

KW - OPC-67683

KW - Tuberculosis

U2 - 10.2147/tcrm.s71076

DO - 10.2147/tcrm.s71076

M3 - Review article

SN - 1176-6336

VL - 11

SP - 779

EP - 791

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

ER -

The role of delamanid in the treatment of drug-resistant tuberculosis

Abstract

UN SDGs

Keywords

Access to Document

Fingerprint

Cite this